pharma · Dravet syndrome · Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
Biocodex
Biocodex clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Gentilly, FR
- Founded
- 1953
- Employees
- 1,648
- Programs
- 5
- Drugs
- 15
- Patents
- 25
Biocodex projects
5 ClinicalTrials.gov programs sponsored by Biocodex.
Biocodex has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BoWell - Sb252
Biocodex
Non-constipated Irritable Bowel Syndrome (IBS)
1 trial -
STP226
Biocodex
Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
1 trial -
STP218
Biocodex
Dravet syndrome
1 trial -
STP237
Biocodex
Patients with renal impairement
1 trial -
Sb 241
Biocodex
Patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis))
1 trial
Frequently asked questions
How many clinical projects does Biocodex have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.